Philadelphia, PA · Founded 2019 · Privately Held (backing)
Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies. Interius BioTherapeutics is based in Philadelphia, PA and was founded in 2019. It was valued at $350 million at a merger or acquisition in Oct 2025, the last priced event on record. It has raised $170 million across 4 recorded rounds; the latest was a $51.4 million later-stage round in May 2024.
PMV mark · valuation
$350.0M
Oct 2026
Priced at
a merger or acquisition
Oct 2025
Total raised
$169.6M
Last round
Later Stage VC
May 2024
Cap table — not yet on record
Interius BioTherapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Interius BioTherapeutics with a free account
·The complete investor list: 20 names
·Watch Interius BioTherapeutics: the Monday email on marks, rounds and moves
Where does Interius BioTherapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Interius BioTherapeutics's 4 recorded funding rounds.
